Prostate cancer treatment costs range from a few thousand dollars for radiation therapy to well over $20,000 for surgery or advanced imaging, depending on the approach your medical team recommends. The total you pay out of pocket depends heavily on your insurance, the stage of your cancer, and whether treatment spans weeks or years. Here’s what to expect across the major treatment options.
Surgery Costs
Radical prostatectomy, the surgical removal of the prostate, is one of the most common treatments for localized prostate cancer. In the U.S., the total billed cost for robotic-assisted prostatectomy typically falls between $15,000 and $30,000 or more, depending on the hospital, your region, and how long you stay. Recovery usually involves a hospital stay of one to three days with robotic surgery, though complications can extend that and push costs higher.
For context, a 2022 Austrian hospital cost analysis put the direct cost of radical prostatectomy at roughly $7,700 (converted from euros), but that reflects a public hospital system with negotiated rates. U.S. prices are significantly higher due to facility fees, surgeon fees, anesthesia, and the cost of robotic equipment. If you’re on Medicare, Part B covers outpatient surgical procedures at 80% after your annual deductible, leaving you responsible for the remaining 20% of approved charges.
Radiation Therapy Costs
Radiation is the other major curative option, and costs vary widely based on the type and number of sessions. The two most common forms are IMRT (intensity-modulated radiation therapy), which typically runs 20 to 39 sessions over several weeks, and SBRT (stereotactic body radiation therapy), which delivers higher doses in just five to seven sessions.
That difference in session count translates directly to cost. A 2025 U.S. study found the estimated total cost per patient was $20,130 for IMRT compared to $9,259 for SBRT for intermediate-risk prostate cancer. SBRT’s lower price comes from fewer treatment visits, less machine time, and fewer associated facility fees. Both approaches have comparable cancer control outcomes for many patients, so the cost gap is significant.
Brachytherapy, where radioactive seeds are implanted directly into the prostate, falls somewhere in between. It’s typically done in one or two procedures and costs roughly $10,000 to $20,000 in the U.S. before insurance, though again, negotiated rates vary. European data puts the direct cost closer to $5,000 in a public hospital setting.
Active Surveillance Costs
For low-risk prostate cancer, many men choose active surveillance: monitoring the cancer closely without immediate treatment. This avoids the upfront cost of surgery or radiation but creates ongoing annual expenses. The main cost drivers are PSA blood tests, clinic visits, periodic MRI scans, and repeat prostate biopsies.
A pelvic MRI runs just over $500 through Medicare reimbursement, though private insurers pay more and hospitals often bill much higher amounts before negotiation. Prostate biopsies generate around $300 in physician reimbursement through Medicare, plus additional facility fees if performed at a surgery center or hospital. Many surveillance protocols call for a biopsy every one to two years, sometimes indefinitely, making biopsies the single largest recurring expense. Over a lifetime, active surveillance for intermediate or high-risk disease can cost $15,000 to $18,000 total in direct medical expenses, comparable to surgery or radiation when you account for the years of monitoring.
PSMA-PET Scans and Staging
If your cancer needs detailed staging, your doctor may order a PSMA-PET scan, a specialized imaging test that highlights prostate cancer cells throughout the body. These scans are expensive. Total charges commonly range from $6,000 to $22,000, though what insurance actually pays is far less. Medicare has negotiated rates around $15,000, and Blue Cross/Blue Shield allowed about $5,500 on a charge of nearly $23,000 in one reported case.
Your out-of-pocket share varies enormously. Patients with insurance have reported copays between $365 and $2,771. Without insurance, expect to pay around $6,000 at a private facility, combining the scan fee (roughly $1,000) with the cost of the radioactive tracer (approximately $5,000). Not all insurance plans cover PSMA-PET scans without prior authorization, so check before scheduling.
Hormone Therapy and Medications
Androgen deprivation therapy (ADT) is commonly used alongside radiation for higher-risk cancers or as a primary treatment for advanced disease. These drugs work by cutting off the testosterone that fuels prostate cancer growth. ADT is typically delivered as an injection every one to six months and can continue for months or years.
The cost of hormone therapy adds up over time. Injections like leuprolide (brand name Lupron) can cost several hundred to over a thousand dollars per dose before insurance. Newer oral medications that block testosterone signaling, such as enzalutamide or apalutamide, are considerably more expensive, often running $10,000 to $15,000 per month at list price. If these oral drugs fall under Medicare Part D (prescription drug coverage), you’ll pay a percentage that shifts as you move through coverage phases: 25% to 37% in the coverage gap, dropping to about 5% once you reach catastrophic coverage.
Advanced and Metastatic Disease
Costs escalate sharply when prostate cancer spreads. Treatments for metastatic disease often combine hormone therapy with newer targeted drugs or immunotherapy, and courses can last months to years.
Sipuleucel-T (Provenge), an immunotherapy for advanced prostate cancer, involves three infusions spaced about two weeks apart. Each infusion requires collecting your immune cells, processing them in a lab, and reinfusing them. The full three-dose course has been widely reported at approximately $93,000. Medicare Part B covers it at 80%, but the 20% coinsurance on a bill that size still represents a substantial expense without supplemental coverage.
Indirect Costs Most People Don’t Expect
Medical bills are only part of the picture. A 2024 study tracking the indirect costs of prostate cancer found that out-of-pocket spending on transportation, parking, meals, and caregiving ranged from $154 to $717 per month. When researchers factored in lost wages for patients and caregivers, travel time, and extra hours dedicated to care, the total indirect costs climbed to $608 to $4,107 per month. Higher-risk disease pushed costs toward the upper end.
Radiation therapy, which may require daily trips to a treatment center for four to eight weeks, generates particularly high travel costs for patients who don’t live near a cancer center. SBRT’s shorter treatment course (five to seven visits versus 20 to 39 for conventional radiation) can meaningfully reduce this burden. Surgery typically involves one major trip but may require follow-up visits for weeks afterward.
How Insurance Shapes What You Pay
Medicare Part B covers most outpatient prostate cancer treatment, including surgery, radiation, chemotherapy given in a clinic, and immunotherapy, at 80% of the approved amount after your annual deductible. You’re responsible for the remaining 20%. For a $20,000 course of radiation, that’s $4,000 out of pocket before any supplemental insurance kicks in.
Oral cancer drugs, including many of the newer hormone-blocking medications, fall under Medicare Part D. Part D has a coverage gap (the “donut hole”) where your cost share rises to 25% to 37% of the drug price. Once your total out-of-pocket spending crosses a yearly threshold, catastrophic coverage drops your share to 5%. For drugs costing $10,000 or more per month, you can reach that threshold quickly.
Private insurance varies widely. Many plans cover the same treatments but with different copay structures, prior authorization requirements, and network restrictions. Out-of-network treatment at a specialized cancer center can double or triple your costs. If you’re comparing treatment options, asking each provider’s billing department for a cost estimate specific to your plan is worth the effort, since the same treatment at two hospitals in the same city can differ by tens of thousands of dollars.
Lifetime Cost by Risk Level
A long-term analysis based on the landmark ProtecT trial tracked lifetime costs for men with localized prostate cancer across three strategies: active monitoring, surgery, and radiation. For men under 65 with intermediate or high-risk disease, lifetime costs ranged from about $15,300 for surgery to $18,300 for active monitoring (in UK pounds, roughly $19,000 to $23,000). The higher long-term cost of monitoring reflects years of testing plus the likelihood of eventually needing treatment anyway.
For men 65 and older, lifetime costs were lower across all strategies, ranging from roughly $9,200 to $10,300 (£), because the monitoring and treatment window is shorter. Radiation was the least costly lifetime option for older men and for those in lower-risk categories. These figures cover direct medical costs only and don’t include the indirect expenses or side-effect management that can add significantly to the real-world total.